Current Report Filing (8-k)
February 26 2021 - 4:21PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): February 22, 2021
ENVERIC
BIOSCIENCES, INC.
(Exact
name of Registrant as specified in its charter)
Delaware
|
|
001-38286
|
|
95-4484725
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
No.)
|
|
(IRS
Employer
Identification
No.)
|
Enveric
Biosciences, Inc.
4851
Tamiami Trail N, Suite 200
Naples,
FL 34103
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: (239) 302-1707
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
stock, par value $0.01 per share
|
|
ENVB
|
|
The
Nasdaq Stock Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
1.01 Entry Into a Material Definitive Agreement
On February 22, 2021,
Enveric Biosciences, Inc. (the “Company”) entered into a Development and Clinical Supply Agreement (the “Agreement”)
with PureForm Global, Inc. (“PureForm”), pursuant to which PureForm will be the exclusive provider of synthetic cannabidiol
(“API”) for the Company’s development plans for cancer treatment and supportive care. Under the terms of the
Agreement, PureForm has granted the Company the exclusive right to purchase API and related product for cancer treatment and supportive
care during the term of the Agreement (contingent upon an initial minimum order volume during the first thirty (30) days from
the effective date) and has agreed to manufacture, package and test the API and related product in accordance with specifications
established by the parties. All inventions that are developed jointly by the parties in the course of performing activities under
the Agreement will be owned jointly by the parties in accordance with applicable law; however, if the Company funds additional
research and development efforts by PureForm, the parties may enter into a further agreement whereby PureForm would assign any
resulting inventions or technical information to the Company.
The
initial term of the Agreement is three (3) years commencing on the effective date of the Agreement, subject to extension by mutual
agreement of the parties. The Agreement may be terminated by either party upon thirty (30) days written notice of an uncured material
breach or immediately in the event of bankruptcy or insolvency. The Agreement contains, among other provisions, representation
and warranties, indemnification obligations and confidentiality provisions in favor of each party that are customary for an agreement
of this nature.
The
description of the terms and conditions of the Agreement set forth herein do not purport to be complete and are qualified in their
entirety by the full text of the Agreement, a copy of which will be filed as an exhibit to the Company’s Quarterly Report
on Form 10-Q for the period ended March 31, 2021.
Item
8.01 Other Events.
On
February 25, 2021, the Company issued a press release regarding the transaction described above under Item 1.01 of this Current
Report on Form 8-K. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ENVERIC
BIOSCIENCES INC.
|
|
|
|
Date:
February 26, 2021
|
By:
|
/s/
John Van Buiten
|
|
|
John
Van Buiten
|
|
|
Chief
Financial Officer
|
Ameri (NASDAQ:AMRH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ameri (NASDAQ:AMRH)
Historical Stock Chart
From Sep 2023 to Sep 2024